A new artificial intelligence tool developed at Cedars-Sinai could transform how clinicians select presurgical therapies for breast cancer patients. The tool, named BRIDGE, was detailed in a recent publication in Annals of Oncology alongside early validation data. Unlike conventional methods that classify a tumor into a single subtype, BRIDGE reads genetic signals inside a tumor to identify which subtypes are present, allowing for more tailored treatment strategies.
Breast cancer is a heterogeneous disease, meaning that a single tumor can contain multiple subtypes with different genetic profiles. This diversity can affect how the tumor responds to treatments such as chemotherapy or hormone therapy. The BRIDGE AI tool aims to address this complexity by analyzing the genetic makeup of the tumor at a finer resolution, potentially leading to more effective presurgical (neoadjuvant) therapy decisions.
The development builds on other advances in cancer research, including work by companies like Calidi Biotherapeutics Inc. (NASDAQ: CLDI), which focuses on developing novel immunotherapies. The integration of AI into oncology is increasingly seen as a key driver of precision medicine, offering the potential to match patients with treatments that are most likely to succeed based on their tumor's unique characteristics.
The BRIDGE tool was validated using data from clinical trials and patient cohorts, demonstrating its ability to predict which patients would benefit from specific neoadjuvant therapies. The researchers at Cedars-Sinai believe that this approach could reduce the use of ineffective treatments, minimize side effects, and improve outcomes for breast cancer patients.
This announcement is part of a broader trend in which AI is being leveraged to analyze complex biomedical data. The implications for patient care are significant: by moving beyond one-size-fits-all treatment paradigms, AI tools like BRIDGE could help oncologists make more informed decisions earlier in the treatment process. As the tool undergoes further validation, it may become a standard component of breast cancer management.
The findings were published in Annals of Oncology, a leading journal in the field. The study's authors emphasized that while the results are promising, additional research is needed to confirm the tool's utility across diverse patient populations and healthcare settings. The development of BRIDGE underscores the potential of AI to improve cancer care by unlocking insights from genomic data that were previously inaccessible.
